Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 13Gastrointestinal 3Head & Neck 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × talimogene laherparepvec × Gastrointestinal × Clear all
NCT02509507 2024-08-06

MASTERKEY-318

Amgen

Phase 1/2 Completed
127 enrolled 37 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Amgen

Phase 1 Completed
36 enrolled 16 charts
BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00402025 2016-04-15

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

BioVex Limited

Phase 1 Completed
17 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡